



WIN SYMPOSIUM COMMITTEE ANNOUNCES THE WIN 2022 SYMPOSIUM PROGRAM!

Integrating Genomics and Transcriptomics to Reshape Precision Oncology: A WINning Strategy

SYMPOSIUM CHAIRS



Richard L. Schilsky

Chairman, WIN Consortium; Professor Emeritus, University of Chicago; past President and former Executive Vice President and Chief Medical Officer (ASCO), USA



Josep Taberero

Vice Chairman & Chair of Scientific Advisory Board, WIN Consortium; Head, Medical Oncology, Vall d'Hebron Institute of Oncology, Barcelona, Spain; past President (2018-2019), European Society for Medical Oncology (ESMO)

COMMITTEE MEMBERS



Gerald Batist

Professor of Medicine and Oncology at McGill University; Director of the Segal Cancer Centre, Canada



Vladimir Lazar

Chief Scientific and Operating Officer, WIN Consortium



Amir Onn

Head of Standard Operating Procedures and Repository Committee, WIN Consortium; Chair, Institute of Pulmonology Oncology, Sheba Medical Center, Israel



Razelle Kurzrock

Chief Medical Officer and Chair of Clinical Trials Committee, WIN Consortium

We are looking forward to finally meeting you again in person at the [WIN 2022 Symposium!](#) Our [12th Annual WIN Symposium](#) will take place on 14-15 March, 2022 in Barcelona, Spain.

As always, WIN Symposium will gather renowned experts in personalized cancer medicine from all over the world, and will explore innovative ways to bolster Precision Oncology by integrating transcriptomics to the current armamentarium of genomics.

Experts will present what the future of Precision Oncology will be, the most recent news on genomic and transcriptomic biomarker strategies for application in the clinic and the latest news on therapeutics for a range of pathologies. [The program is now complete.](#)

We are delighted to present some of our renowned speakers:

WELCOME AND OPENING KEYNOTE LECTURE *featuring:*



Vivek Subbiah

Re-imagining the (r)evolution in the Precision Oncology paradigm: The future is now

Vivek Subbiah
(The University of Texas, MD Anderson Cancer Center, Houston, USA)

SESSION 1 - BEYOND DNA TESTING: THE PLACE OF TRANSCRIPTOMICS IN PRECISION ONCOLOGY *will address the new era of transcriptomics for treatment decision in the clinic featuring Keynote Lectures:*



Louis M. Staudt

Expression profiling to discover molecularly and clinically distinct cancer subtypes and to predict response to therapy

Louis M. Staudt
(National Cancer Institute (NCI), Bethesda, USA)



René Bernards

Functional genomics to identify cancer vulnerabilities

René Bernards
(Netherlands Cancer Institute (NKI), Amsterdam, The Netherlands)

SESSION 2 - INNOVATION IN CLINICAL TRIALS TO ENABLE FUTURE EFFICIENT TREATMENTS *with Keynote speakers exploring single cell opportunity and information from the real world:*



Andrea Califano

Bringing single cell analyses to the clinics

Andrea Califano
(Columbia University Medical Center, New York, USA)



Richard L. Schilsky

Identifying new uses for approved, targeted drugs: Updates from the ASCO TAPUR study

TAPUR trial investigator Richard L. Schilsky
(Chairman, WIN Consortium; Professor Emeritus, University of Chicago; past President and former Executive Vice President and Chief Medical Officer (ASCO), USA)

SESSION 3 - DISRUPTIVE CONCEPTS AND METHODOLOGICAL INNOVATIONS IN NSCLC: MEET THE EXPERTS *with Keynote Lecture:*



Solange Peters


Advances in Lung Cancer

Solange Peters, President ESMO 2020-2022
(Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland)

Experts in the session include: Fiona Blackhall (The Christie and Manchester Cancer Research Centre, UK) and speakers from the WIN Consortium: Haiquan Chen (Fudan University, China), Enriqueta Felip (VHIO, Spain), Jair Bar (Chaim Sheba Medical Center, Israel), Benjamin Solomon (Avera Cancer Institute, USA).



Fiona Blackhall



Haiquan Chen



Enriqueta Felip



Jair Bar



Benjamin Solomon


SESSION 4 - WIN FIRST INTERNATIONAL MOLECULAR TUMOR BOARD: A STRATEGIC PLACE IN ADVANCING PRECISION ONCOLOGY



Razelle Kurzrock

Razelle Kurzrock (CMO, WIN Consortium) will be moderating the first Molecular Tumor Board discussing WIN members' patients across the world followed by discussion with the audience.


SESSION 5 - WHAT IS NEW IN BREAST, CRC, OVARY, HEAD & NECK, PROSTATE, KIDNEY, PEDIATRIC CANCERS? *in particular Keynote talks:*



Martine Piccart

The BIG AURORA molecular screening program for metastatic breast cancer: first results

Martine Piccart
(Institut Jules Bordet, Brussels, Belgium)



Sabine Tejpar

Novel CRC insights based on combined genomic and transcriptomic data at both bulk and single cell level, leading to new therapeutically relevant CRC classification

Sabine Tejpar
(University of Leuven, Belgium)